MedTrace Logo

A Trial of APPA in the Treatment of Knee Osteoarthritis

NCT04657926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2021-11-17

No results posted yet for this study

Summary

A placebo controlled study of APPA in 150 participants with Osteoarthritis of the knee

Conditions

Interventions

DRUG

APPA

APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

  • NBCD A/S

    collaborator INDUSTRY

  • AKL Research and Development

    lead INDUSTRY

Principal Investigators

  • Asger Bihlet · Nordic Bioscience Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2021-09-30
Completion
2021-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04657926 on ClinicalTrials.gov